Solvonis Therapeutics PLC

“"Certain directors of the Company and another person discharging managerial responsibilities on its behalf intend to participate in the Fundraise but it is not available to the public generally." Issuing 2,074,378,528 Consideration Shares for Awakn acquisition on top of fundraise shares.”

Explicit exclusion of the public from the fundraise while directors participate creates a selective access concern. The combined dilution from both the fundraise shares and the Awakn acquisition consideration shares is substantial but the total dilutive impact is not clearly quantified upfront.

“AWKN-001 is a Phase 3 novel investigational combination therapy for severe AUD with targeted regulatory pathways in the UK and EU that may confer up to 10 years of regulatory data and market protection...approximately 40 million individuals across the U.S. and key European markets”

Forward-looking claims about regulatory exclusivity periods and large addressable patient populations presented in a fundraise context for a company acquiring clinical-stage assets. The 40 million patient figure, while qualified, is used to frame the investment case.